@entity4089 is common in @entity1 with @entity177 . Because radiographic contrast material given during a computed tomographic (CT) scan of the sella as part of the evaluation for @entity2013 worsens @entity177 , we attempted to define the point at which @entity4089 becomes an expected finding in @entity1 with @entity177 in this study. Of 59 patients with serum @entity1011 levels of 1.5 to 12 mg/dL, 16 (27.1%) were hyperprolactinemic. Of these 16, nine were not taking medications known to raise @entity4090 levels and their @entity4090 levels were less than 100 ng/mL. In the eight @entity1 taking medications @entity4090 levels were much higher. In one @entity1 the @entity4090 level fell from 2,210 to 100 ng/mL when methyldopa was discontinued. In @entity1 with @entity177 @entity4090 levels were similar regardless of the method of dialysis. We conclude that in the absence of medications known to affect @entity4090 secretion, @entity4089 occurs infrequently (18.3%) and, when it occurs, is mild (less than 100 ng/mL). Marked @entity4089 may occur in @entity1 taking such medications. These should be stopped and the @entity4090 level rechecked before a CT scan is performed.

@entity4089 in @entity1 with @entity177 and XXXX requiring hemodialysis or chronic ambulatory peritoneal dialysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity4089 :: ('MESH:D006966', 'Disease') :: ['Hyperprolactinemia', 'hyperprolactinemia'] @entity2013 :: ('MESH:D015175', 'Disease') :: ['prolactinoma'] @entity4090 :: ('5617', 'Gene') :: ['prolactin'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure', 'renal insufficiency', 'chronic renal failure'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']
@entity177 :: (MESH:D051437,Disease) :: ['chronic renal failure']
